311 related articles for article (PubMed ID: 21114393)
1. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of resistant Pseudomonas aeruginosa with elective and rescue intravenous antibiotic regimens in children with cystic fibrosis.
Smyth E; David TJ; Patel L; Ashcroft P; Sanyal D; Vyas J
Int J Antimicrob Agents; 2005 Jul; 26(1):95-6. PubMed ID: 15970432
[No Abstract] [Full Text] [Related]
4. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
Stockmann C; Sherwin CM; Zobell JT; Young DC; Waters CD; Spigarelli MG; Ampofo K
Pediatr Pulmonol; 2013 Mar; 48(3):211-20. PubMed ID: 22949224
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
[TBL] [Abstract][Full Text] [Related]
6. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
7. [Antibiotic inhalation in cystic fibrosis. A review of the literature].
Steinkamp G
Monatsschr Kinderheilkd; 1991 Feb; 139(2):73-80. PubMed ID: 1903843
[TBL] [Abstract][Full Text] [Related]
8. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
Goldfarb J; Stern RC; Reed MD; Yamashita TS; Myers CM; Blumer JL
Am J Med; 1987 Apr; 82(4A):174-9. PubMed ID: 3555032
[TBL] [Abstract][Full Text] [Related]
9. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
Antonela Antoniu S
Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
[TBL] [Abstract][Full Text] [Related]
10. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Stass H; Delesen H; Nagelschmitz J; Staab D
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
[TBL] [Abstract][Full Text] [Related]
13. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
14. Ciprofloxacin therapy in cystic fibrosis.
Scully BE; Nakatomi M; Ores C; Davidson S; Neu HC
Am J Med; 1987 Apr; 82(4A):196-201. PubMed ID: 3555036
[TBL] [Abstract][Full Text] [Related]
15. Safety of ciprofloxacin in children with cystic fibrosis.
Orenstein DM; Pattishall EN; Noyes BE; Kurland G; Hartigan ER; Yu VL
Clin Pediatr (Phila); 1993 Aug; 32(8):504-6. PubMed ID: 8403750
[No Abstract] [Full Text] [Related]
16. Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
Millar BC; Malnarcic CM; McCaughan J; Moore JE
Clin Respir J; 2020 Jan; 14(1):64-68. PubMed ID: 31663261
[No Abstract] [Full Text] [Related]
17. Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations.
Khachman D; Conil JM; Georges B; Saivin S; Houin G; Toutain PL; Laffont CM
J Antimicrob Chemother; 2011 Aug; 66(8):1798-809. PubMed ID: 21653603
[TBL] [Abstract][Full Text] [Related]
18. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis.
Rubio TT
Diagn Microbiol Infect Dis; 1990; 13(2):153-5. PubMed ID: 2114953
[No Abstract] [Full Text] [Related]
19. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
